Kitagawa, Y.; Shimada, H.; Mori, R.; Tanaka, K.; Wakatsuki, Y.; Onoe, H.; Kaneko, H.; Machida, Y.; Nakashizuka, H.
One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. J. Clin. Med. 2022, 11, 2175.
https://doi.org/10.3390/jcm11082175
AMA Style
Kitagawa Y, Shimada H, Mori R, Tanaka K, Wakatsuki Y, Onoe H, Kaneko H, Machida Y, Nakashizuka H.
One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. Journal of Clinical Medicine. 2022; 11(8):2175.
https://doi.org/10.3390/jcm11082175
Chicago/Turabian Style
Kitagawa, Yorihisa, Hiroyuki Shimada, Ryusaburo Mori, Koji Tanaka, Yu Wakatsuki, Hajime Onoe, Hiroyuki Kaneko, Yumiko Machida, and Hiroyuki Nakashizuka.
2022. "One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy" Journal of Clinical Medicine 11, no. 8: 2175.
https://doi.org/10.3390/jcm11082175
APA Style
Kitagawa, Y., Shimada, H., Mori, R., Tanaka, K., Wakatsuki, Y., Onoe, H., Kaneko, H., Machida, Y., & Nakashizuka, H.
(2022). One-Year Outcome of Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injections for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy. Journal of Clinical Medicine, 11(8), 2175.
https://doi.org/10.3390/jcm11082175
